You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, MA, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus (HCV). Tyzeka/Sebivo for the treatment of Hepatitis B, co-developed by Idenix Pharmaceuticals, Inc. and Novartis Pharma AG, is currently available. Four other treatments are in preclinical to phase II development as of October 2009.
| Ticker: | IDIX |
| ISIN: | US45166R2040 |
| Address: |
60 Hampshire Street |
| Cambridge, MA, 02139, USA | |
| Website: | Idenix Pharmaceuticals, Inc. |
| Phone #: | 617-995-9800 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Pharmaceutical & Medicine Manufacturing |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.